<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00707603</url>
  </required_header>
  <id_info>
    <org_study_id>H04/126</org_study_id>
    <nct_id>NCT00707603</nct_id>
  </id_info>
  <brief_title>Chronic Hepatitis C and Insulin Resistance</brief_title>
  <official_title>Understanding the Relationship Between Insulin Resistance and Chronic Hepatitis C Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Garvan Institute of Medical Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Garvan Institute of Medical Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic hepatitis C (CHC) is among the commonest chronic infectious disease in Australia with
      &gt;200,000 exposed persons. Amongst non-infectious chronic conditions- Type 2 diabetes, obesity
      and heart disease are extremely common. This study will examine the relationship between
      insulin resistance, fat deposition in the liver, muscle and abdomen, and liver injury due to
      CHC
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin Resistance by euglycaemic hyperinsulinaemic clamp Liver fat, abdominal fat and muscle fat measures</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>insulin resistance post treatment of Hep C</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">50</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Hepatitis C subjects</arm_group_label>
    <description>Due to start therapy for Hepatitis C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Healthy males</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hepatitis C patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Caucasian male

          -  Age: 25-55 years

          -  Chronic Hepatitis C (PCR positive) and fibrosis â‰¤ F2 (if liver biopsy done)

          -  Genotypes 1 or 3

          -  Due to commence antiviral therapy

          -  BMI &lt; 30

        Exclusion Criteria:

          -  Cirrhosis or F3 fibrosis on liver biopsy (if done)

          -  &gt; 20 g ETOH per day

          -  Type 2 Diabetes (need an OGTT if fasting BGL&gt; 5.7)

          -  Concurrent HIV

          -  Other cause of liver disease
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald Chisholm, MBBS, FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Garvan Institute of Medical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacob George, MBBS, FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Storr Liver Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Garvan Institute Of Medical Research</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Storr Liver Unit</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2008</study_first_submitted>
  <study_first_submitted_qc>June 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2008</study_first_posted>
  <last_update_submitted>July 13, 2015</last_update_submitted>
  <last_update_submitted_qc>July 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Garvan Institute of Medical Research</investigator_affiliation>
    <investigator_full_name>Dr Jerry Greenfield</investigator_full_name>
    <investigator_title>Head of Endocrinology Department St Vincent's Hospital Sydney</investigator_title>
  </responsible_party>
  <keyword>Insulin resistance</keyword>
  <keyword>Liver fat</keyword>
  <keyword>Muscle fat</keyword>
  <keyword>Abdominal fat</keyword>
  <keyword>Cytokines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

